You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,536,161


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,536,161
Title:Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
Abstract: Combinations of PI3K inhibitor compounds having Formula I and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for treating hematopoietic malignancies. Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##
Inventor(s): Ebens, Jr.; Allen J. (San Carlos, CA), Friedman; Lori (San Carlos, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:12/721,645
Patent Claims:1. A method for the treatment of a hematopoietic malignancy comprising administering a therapeutic combination as a combined formulation or by alternation to a mammal in need thereof, wherein the therapeutic combination comprises a synergistically effective amount of a compound having Formula I or pharmaceutically acceptable salt thereof, and a synergistically effective amount of one or more chemotherapeutic agents selected from dexamethasone, doxorubicin, rituximab, prednisone, lenalidomide, bortezomib, and rapamycin; wherein the Formula I compound is 4-(2-(1H-indazol-4-yl)-6-((4-(methylsulfonyl)piperazin-1-yl)methyl)thi- eno[3,2-d]pyrimidin-4-yl)morpholine having Formula Ia: ##STR00056##

2. The method of claim 1 wherein the chemotherapeutic agent is dexamethasone.

3. The method of claim 1 wherein the chemotherapeutic agent is doxorubicin.

4. The method of claim 1 wherein the chemotherapeutic agent is rituximab.

5. The method of claim 1 wherein the chemotherapeutic agent is prednisone.

6. The method of claim 1 wherein the chemotherapeutic agent is lenalidomide.

7. The method of claim 1 wherein the chemotherapeutic agent is bortezomib.

8. The method of claim 1 wherein the chemotherapeutic agent is rapamycin.

9. The method of claim 1 wherein the therapeutic combination further comprises cyclophosphamide and vincristine.

10. The method of claim 1 wherein the pharmaceutically acceptable salt of the Formula I compound is selected from a salt formed with hydrochloric acid, hydrobromic acid, hydroiodic acid, sulphuric acid, nitric acid, phosphoric acid, methanesulfonic acid, benzenesulphonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, ethanesulfonic acid, aspartic acid and glutamic acid.

11. The method of claim 1 wherein the synergistically effective amount of a compound having Formula I, and the synergistically effective amount of the chemotherapeutic agent are administered as a combined formulation.

12. The method of claim 1 wherein the synergistically effective amount of a compound having Formula I, and the synergistically effective amount of the chemotherapeutic agent are administered to a mammal by alternation.

13. The method of claim 12 wherein the mammal is administered with the chemotherapeutic agent and subsequently administered with the Formula I compound.

14. The method of claim 12 wherein the therapeutic combination is administered by a dosing regimen where the synergistically effective amount of a compound having Formula I is administered in a range from twice daily to once every three weeks, and the synergistically effective amount of the chemotherapeutic agent is administered in a range from twice daily to once every three weeks.

15. The method of claim 14 wherein the dosing regimen is repeated one or more times.

16. The method of claim 1 wherein administration of the therapeutic combination results in a synergistic effect.

17. The method of claim 1 wherein the hematopoietic malignancy is selected from non-Hodgkin's lymphoma, diffuse large hematopoietic lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, multiple myeloma, AML, and MCL.

18. The method of claim 1 wherein the Formula I compound and the chemotherapeutic agent are each administered in an amount from about 1 mg to about 1000 mg per unit dosage form.

19. The method of claim 1 wherein the Formula I compound and the chemotherapeutic agent are administered in a ratio of about 1:50 to about 50:1 by weight.

Details for Patent 8,536,161

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2039-02-26
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2039-02-26
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.